Ascendis Pharma A/S

NASDAQ:ASND

Biotechnology

Healthcare
$270.33 -0.02%

-$0.05 today

Market cap
$17.73B
Beta
0.39
P/E (TTM)
24.5
EPS (TTM)
$8.21
52W Low $160.86High $250.74

Volume 0.57M

Average 0.64M

ASND Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Ascendis Pharma A/SNASDAQ: ASND

Operating Expenses · Q3 FY2026 · quarter ended Sep 2026

Operating expenses grows, but more slowly than its trailing trend

Q3 FY2026 operating expenses of €211.32M rose 17.2% year over year, behind the +23.4% change in trailing-twelve-month operating expenses. Sequentially, it fell 15.2% from the prior quarter. Over 3 fiscal years it compounded at +6.2% a year.

Context

  • Operating expenses amounted to 104.0% of revenue in FY2025, down 60.5 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +17.2% toward the trailing-twelve-month pace of +23.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
€211.32M-15.2% QoQ
Last fiscal yearDec 2025
€719.42M+20.3% YoY
LTMSep 2026
€872.49M+23.4% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.2%——
1 year+20.3%——
3-year CAGR+6.2%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

EUR · from the income statement

Latest · FY2025
719.42M EUR
Year-over-year change
+20.3%
4-year CAGR
+12.1%

Operating Expenses vs competitors

How ASND compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +23.4% is the 8th highest of 11, against a peer median of +34.8%.
  • Operating expenses amounts to 72.2% of revenue for ASND, versus a peer median of 97.5%.
ASND Competitors
Operating Expenses for ASND and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$902.93B USD+47406.7%+10.9%87.9%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$2.74B USD+31.1%+21.6%74.0%
INSMInsmed IncorporatedLTM Jun 2026$1.76B USD+35.1%+36.8%155.1%
UTHRUnited Therapeutics CorporationLTM Jun 2026$1.31B USD+1.8%+16.5%41.7%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$1.12B USD+10.3%+3.8%167.5%
ASNDAscendis Pharma A/SLTM Sep 2026€872.49M EUR+23.4%+6.2%72.2%
CORTCorcept Therapeutics IncorporatedLTM Jun 2026$810.32M USD+34.5%+35.3%97.5%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$220.98M USD+9.0%+8.0%70.2%
STOKStoke Therapeutics, Inc.LTM Mar 2026$214.24M USD+41.4%+20.6%667.8%
SEPNSepterna, Inc.LTM Sep 2026$169.24M USD+70.9%—175.8%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$160.33M USD+76.4%+57.4%—
Peer median (excluding ASND) —+34.8%+20.6%97.5%

Competitors are the stored peer set for ASND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.78M51.17M266.72M363.64M691.71M
Cost of Revenue3.52M12.14M44.4M44.26M103.18M
Gross Profit4.26M39.04M222.32M319.38M588.53M
Gross Margin54.7%76.3%83.4%87.8%85.1%
Research & Development295.87M379.62M413.45M307M283.5M
Selling, General & Admin160.18M215.85M258.79M284.55M435.92M
Operating Expenses456.05M600.85M677.86M598.15M719.42M
Depreciation & Amortization15.39M17.96M18.91M17.71M17M
EBITDA(364.64M)(529.18M)(411.17M)(290.02M)(109.8M)
EBITDA Margin-4688.1%-1034.1%-154.2%-79.8%-15.9%
Operating Income(451.79M)(561.81M)(455.54M)(278.76M)(130.89M)
Operating Margin-5808.6%-1097.9%-170.8%-76.7%-18.9%
Interest Income692K7.43M16.86M14.36M14.7M
Interest Expense3.91M30.68M44.07M65.5M77.46M
Other Income / Expenses67.85M(16M)(18.6M)(94.48M)(73.37M)
Income Before Tax(383.94M)(577.82M)(474.14M)(373.24M)(204.26M)
Pre-Tax Margin-4936.3%-1129.1%-177.8%-102.6%-29.5%
Income Tax Expense(367K)5.38M7.3M4.84M14.78M
Net Income(383.58M)(583.19M)(481.45M)(378.08M)(219.03M)
Net Margin-4931.6%-1139.6%-180.5%-104.0%-31.7%
EPS (Basic)(7.00)(10.40)(8.55)(6.53)(3.62)
EPS (Diluted)(7.00)(10.40)(8.55)(6.53)(3.62)
Weighted Avg Shares54.77M56.07M56.29M57.89M60.61M
Weighted Avg Shares (Diluted)54.77M56.07M56.29M57.89M60.61M

Ascendis Pharma A/S

NASDAQ:ASND

Intrinsic Alpha fair value

Locked

Current Price

$270.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.